CNBX Pharmaceuticals Statistics
Total Valuation
CNBX has a market cap or net worth of 225,959. The enterprise value is 1.55 million.
| Market Cap | 225,959 |
| Enterprise Value | 1.55M |
Important Dates
The next estimated earnings date is Monday, December 1, 2025.
| Earnings Date | Dec 1, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
CNBX has 753.20 million shares outstanding. The number of shares has increased by 21.59% in one year.
| Current Share Class | 753.20M |
| Shares Outstanding | 753.20M |
| Shares Change (YoY) | +21.59% |
| Shares Change (QoQ) | +32.72% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | 1.62% |
| Float | 752.47M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | -0.09 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -6.92 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.01
| Current Ratio | 0.01 |
| Quick Ratio | 0.01 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -7.35 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -246.46% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | 7.67% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -112,226 |
| Employee Count | 2 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -95.40% in the last 52 weeks. The beta is -0.34, so CNBX's price volatility has been lower than the market average.
| Beta (5Y) | -0.34 |
| 52-Week Price Change | -95.40% |
| 50-Day Moving Average | 0.00 |
| 200-Day Moving Average | 0.00 |
| Relative Strength Index (RSI) | 49.11 |
| Average Volume (20 Days) | 12,288,898 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.00 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -194,494 |
| Pretax Income | -224,451 |
| Net Income | -224,451 |
| EBITDA | -140,254 |
| EBIT | -194,494 |
| Earnings Per Share (EPS) | -0.01 |
Balance Sheet
The company has 13,648 in cash and 1.34 million in debt, giving a net cash position of -1.33 million or -0.00 per share.
| Cash & Cash Equivalents | 13,648 |
| Total Debt | 1.34M |
| Net Cash | -1.33M |
| Net Cash Per Share | -0.00 |
| Equity (Book Value) | -2.54M |
| Book Value Per Share | -0.03 |
| Working Capital | -2.54M |
Cash Flow
| Operating Cash Flow | -191,010 |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CNBX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -21.59% |
| Shareholder Yield | -21.59% |
| Earnings Yield | -99.33% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on May 12, 2022. It was a reverse split with a ratio of 0.0083333.
| Last Split Date | May 12, 2022 |
| Split Type | Reverse |
| Split Ratio | 0.0083333 |
Scores
CNBX has an Altman Z-Score of -2087.09 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -2087.09 |
| Piotroski F-Score | 1 |